通过调整肺癌临床路径标准化局部晚期非小细胞肺癌的放疗剂量
在大型综合癌症中心网络中,研究者评估了基于RTOG 0617结果对非小细胞肺癌临床路径的修改对实践的影响。2016年1月将路径修改为60-70 Gy后,99%的决策剂量≤66 Gy;
要点
- RTOG 0617发表后,处方剂量中位数从66 Gy降至60 Gy。
- 路径修改后,99%的决策剂量≤66 Gy。
- 路径是确保患者接受循证治疗的有效工具。
核心结论
- 临床路径可消除导致不良结局的实践差异,确保患者接受循证治疗。
研究设计与样本
- 在2001年实施针对IIIA/IIIB期NSCLC根治性放化疗的临床路径,2013年修改允许60-74 Gy,2016年1月修改为60-70 Gy,分析2012-2016年决策数据。
主要发现
- 从2012年至2015年2月RTOG 0617发表,处方剂量中位数为66 Gy(分次1.8-2.1 Gy),52%患者剂量≤66 Gy。
- 2015年2月至2016年9月,处方剂量中位数为60 Gy,91%处方剂量≤66 Gy。
- 路径修改2后,99%决策剂量≤66 Gy。
关键数值与推荐
- 路径修改2指定剂量范围为60-70 Gy,更高剂量视为路径外并需同行评议。
临床怎么用
- 在大型癌症中心网络中,通过修改临床路径可标准化局部晚期NSCLC的放疗剂量,促进循证实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The results of Radiation Therapy Oncology Group (RTOG) 0617, which randomized patients with stages IIIA/IIIB non-small cell lung cancer (NSCLC) to definitive chemoradiation therapy to 60 Gy versus 74 Gy, demonstrated a detrimental survival impact with high-dose radiation therapy. We evaluated the impact of changes to a provider-driven clinical pathway (CP) guiding management of NSCLC on practice throughout our cancer center network. METHODS AND MATERIALS: In 2001, we implemented a CP for management of stage IIIA/IIIB NSCLC with definitive chemoradiation therapy. In 2013, the CP for NSCLC was amended (amendment 1) to allow a dose range of 60 to 74 Gy. The CP was amended (amendment 2) in January 2016 to specify a dose range of 60 to 70 Gy. Higher doses were considered off-pathway and subject to peer review. Data from decisions entered from 2012 to 2016 were obtained. RESULTS: From 2012 until publication of RTOG 0617 in February 2015, the median prescription dose was 66 Gy delivered in 1.8 to 2.1 Gy fractions. Doses ≤66 Gy were prescribed for 52% of patients. From February 2015 to September 2016, the median prescription dose was 60 Gy, and 91% of prescription doses were ≤66 Gy. After amendment 2, 99% of decisions were ≤66 Gy. Dose ≤66 Gy was associated with treatment following publication of 0617 (P < .001) and treatment after amendment 2 (P < .001). On multivariable analysis, treatment after amendment 2 was associated with dose ≤66 Gy (odds ratio, 9.9; 95% confidence interval, 5.2-19.0; P < .001). The percentage of lung receiving 20 Gy was lower following publication of 0617 (P < .001). There was no difference in the percentage of heart receiving 40 Gy. CONCLUSIONS: CPs eliminate variations in practice that lead to inferior outcomes. Recognizing that our CP for definitive treatment of patients with locally advanced NSCLC allowed heterogeneous dose prescriptions, we modified the CP based on the publication of RTOG 0617. We found that the CP was a tool to ensure patients receive evidence-based care across a large cancer center network.
引用
- Karukonda P, Gebhardt BJ, Horne ZD, et al. Standardization of radiation therapy dose for locally advanced non-small cell lung cancer through changes to a lung cancer clinical pathway in a large, integrated comprehensive cancer center network. Pract Radiat Oncol. 2017. PMID: 28867544. doi:10.1016/j.prro.2017.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。